Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Anti-epileptic Drugs Market – Insights

Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy. The number of available anti-epilepsy drugs (AEDs) have doubled over the past few decades and for the treatment of pediatric epilepsy, nine new drugs were launched in the last decade, as benefits of the medicines are higher than subsequent side-effects from the medicine. Third generation epilepsy drugs (brivaracetam (BRI), carabersat (CRB) and carisbamate (CBM)) are rapidly replacing second and first generation drugs, as they are more safe and tolerable compared to previous generation drugs.

The global anti-epileptic drugs market is estimated to be valued at US$ 7,155.6 million in 2019, and is expected to exhibit a CAGR of 6.6% over the forecast period (2019-2027).

Global Anti-epileptic Drugs Market Share (%) Analysis, By Generation, 2019

Anti-epileptic Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing focus of market players on unmet needs of patients with refractory epilepsy is expected to drive growth of the global anti-epileptic drugs market.

The add-on treatments designed by market players for the treatment of epilepsy with fewer side effects at affordable prices are expected to propel demand for novel AEDs. For instance, some of the market players are engaged in the research and development of epilepsy drugs such as Zogenix Inc., INSYS Therapeutics Inc., and Eisai. Moreover, the market players are entering the market with pipeline drugs initially seeking approval from the U.S. FDA as adjunctive therapies in the refractory partial-seizure population, addressing epilepsy patient’s greatest unmet need.  

The pipeline drugs are currently in stages of development, and are designed to have fewer drug interactions, improved side effect profiles, and overall enhanced safety. This addresses a major need in the anti-epileptic drug, since most of the old mainstay treatments such as carbamazepine, valproate, and phenytoin, are effective, but have very poor safety profiles and are not well tolerated by pediatric patients.

Global Anti-epileptic Drugs Market – Restraints

However, complementary and alternative medicine (CAM) such as ketogenic diet, modified Atkins diet (MAD), and low glycemic index treatment (LGIT) are widely adopted for the treatment of epilepsy among children, in addition to AEDs, which is expected to hamper the market growth.

For instance, according to the Clinical Nutrition Research (a research study conducted to examine the consumption of nutritional supplements to treat a number of diseases), in 2016, around 30% of the children suffering from uncontrolled epileptic seizures were untreated, worldwide, where ketogenic diet (KD) can be an alternative medical treatment for these children, thus restraining the AED market growth. Furthermore, lack of evidence about the effectiveness of newer and expensive drugs compared to cheaper older compounds is expected to hamper the market growth over the forecast period.

Global Anti-epileptic Drugs Market - Regional Insights

On the basis of region, the global anti-epileptic drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global anti-epileptic drugs market, owing to increasing prevalence of epilepsy and launches of generic drug. For instance, according to the Centers for Disease Control and Prevention, in 2017, around 3.4 million people had active epilepsy in the U.S., which included 3 million adults and 470,000 children. In addition, in August 2019, Dr. Reddy’s Laboratories launched generic anti-epileptic Vigabatrin powder, an oral solution in the U.S. market for the treatment of partial seizure.

Asia Pacific is expected to be the fastest growing region in the global anti-epileptic drugs market, owing to increasing product launches by key players in this region. For instance, in February 2020, Eisai Co., Ltd. launched antiepileptic drug (AED), Fycompa, indicated for adjunctive treatment of partial onset seizures in epilepsy patients aged 12 years and above.

Moreover, in 2016, Daiichi Sankyo Company launched vimpat tablets 50 mg and 100 mg for adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in patients with epilepsy.

Global Anti-epileptic Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Anti-epileptic Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Global Anti-epileptic Drugs Market - Competitive Landscape

Key players operating in the global anti-epileptic drugs market include Novartis  AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., Bausch Health Companies Inc., and UCB S.A.

Epilepsy is associated with disrupted activities in the brain known as seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Seizures are further classified into mild seizures and stronger seizures depending on the severity of the seizures. The diagnosis of mild seizures are difficult, as its lasts only for few seconds. Stronger seizures may last for a few seconds to several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure.

Market Dynamics

Epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. The increasing prevalence of epilepsy across the globe is expected to drive growth of the anti-epileptic drugs market over the forecast period. For instance, according to the World Health Organization (WHO) report of 2019, around 50 million people worldwide suffered from epilepsy, making it one of the most common neurological diseases, globally.

Furthermore, epilepsy has high prevalence among the pediatric population. For instance, according to the American Academy of Pediatrics data published in April 2017, epilepsy affects 0.5% to 1% of children globally and is the most frequently occurring chronic neurologic condition in childhood.

Around one-third of children with epilepsy can be assigned to a specific epilepsy syndrome, as defined by the most recently proposed system for organization of epilepsy syndrome. Moreover, according to the Society of Neuroscience, in 2015, epilepsy affected around 10.5 million children, worldwide, and the types and severity of the disorder varied significantly. The common cause of epilepsy includes brain damage due to tumors, Infectious diseases such as meningitis, genetic conditions, and lack of oxygen to the brain at birth.

However, side effects of drugs is major restraining factor for anti-epileptic drugs market growth, which is expected to hamper the market growth over the forecast period. For instance, according to the Journal of Family Practice the side effects of anti-epileptic drugs such as Phenytoin, which causes a pattern of defects collectively called Fetal Hydantoin Syndrome (FHS) characterized by variable degrees of hypoplasia and ossification of the distal phalanges and craniofacial abnormalities. Moreover, Phenobarbital has been associated with an increase in congenital defects when used for epilepsy, but not for other indications.

A syndrome associated with Carbamazepine results in minor craniofacial defects, fingernail hypoplasia, and developmental delay. Moreover, this drug may cause neural-tube defects (NTDs). Carbamazepine, Phenytoin, Primidone, and Phenobarbital affect folate metabolism or absorption, and this may increase the risk of birth defects, including NTDs.

Key features of the study:

  • This report provides in-depth analysis of the global anti-epileptic drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period, 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global anti-epileptic drugs market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study include Novartis  AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., Bausch Health Companies Inc., and UCB Pharma Limited
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological upgradation, market expansion, and marketing tactics
  • The global anti-epileptic drugs market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for global anti-epileptic drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Anti-epileptic Drugs Market, by  Generation:
    • First Generation
    • Second Generation
    • Third Generation
  • Global Anti-epileptic Drugs Market, by Route of Administration:
    • Oral
    • Intravenous
  • Global Anti-epileptic Drugs Market, by Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Anti-epileptic Drugs Market, by Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Generation:
        • First Generation
        • Second Generation
        • Third Generation
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Generation:
        • First Generation
        • Second Generation
        • Third Generation
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Generation:
        • First Generation
        • Second Generation
        • Third Generation
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Generation:
        • First Generation
        • Second Generation
        • Third Generation
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Generation:
        • First Generation
        • Second Generation
        • Third Generation
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Generation:
        • First Generation
        • Second Generation
        • Third Generation
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Novartis  AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • GlaxoSmithKline Plc
    • Johnson & Johnson Service, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • SANOFI S.A.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Mylan N.V.
    • Bausch Health Companies Inc.
    • UCB S.A.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Generation
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Drug Development and Evolution
    • Regulatory Scenario
    • Epilepsy Initiatives Supporting R&D
    • Packaging Requirements for Epilepsy Drugs
    • Various Packaging Solutions for Epilepsy Drugs
    • Key Highlights
    • Pipeline Analysis
    • PEST Analysis
    • Epidemiology
  4. Global Anti-epileptic Drugs Market, By Generation, 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • First Generation
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Second Generation
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Third Generation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  5. Global Anti-epileptic Drugs Market, By Route of Administration, 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Intravenous
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Anti-epileptic Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Anti-epileptic Drugs Market, By Region, 2019 – 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Generation, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Generation, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Generation, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Generation, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Generation, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Generation, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Novartis  AG *
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Johnson & Johnson Service, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sumitomo Dainippon Pharma Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bausch Health Companies Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • UCB S.A.
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 35 market data tables and 30 figures on "Anti-epileptic Drugs Market” - Global forecast to 2027”

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner